SHELTON, CONNECTICUT / ACCESS Newswire / November 14, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs ...
Anil R. Diwan, PhD, President and Executive Chairman of the Company will provide an update on the Company, its Drug Pipeline and Platform Technologies available for licensing. NanoViricides’ Current ...
The Company believes that since remdesivir is already US FDA approved, our drug candidate encapsulating remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed ...
Fresenius Kabi has launched its denosumab biosimilars Conexxence® and Bomyntra® across Europe following European Commission approval in July 2025 for all indications of their reference medicines ...
Today, Novo Nordisk announced the submission of a sNDA to the U.S. Food and Drug Administration (FDA) for a higher dose of ...
Poherdy can be dispensed as a substitute for Perjeta without requiring a prescription change from a health care provider.
The Inflation Reduction Act (IRA) of 2022 mandates price negotiations for certain drugs under Medicare, shortening the exclusivity period historically used to recoup research and development ...
WASHINGTON (AP) — The head of the Food and Drug Administration’s drug center abruptly resigned Sunday after federal officials began reviewing “serious concerns about his personal conduct,” according ...
Adolescents and young adults on TMP-SMX have a higher 30-day risk of acute respiratory failure than those on amoxicillin or cephalosporins. The study supports the FDA's warning about TMP-SMX, with ...
Discontinuing GLP-1 RAs before or during early pregnancy is linked to increased gestational weight gain and pregnancy complications. GLP-1 RAs are not recommended during pregnancy due to potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback